How do I set a price alert for 0HOY.L?

To set a 0HOY.L price alert on Stock Alarm Pro, navigate to the 0HOY.L quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for 0HOY.L?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for 0HOY.L. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for 0HOY.L?

Stock Alarm Pro supports over 125 trigger types for 0HOY.L: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about 0HOY.L price changes?

0HOY.L alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for 0HOY.L alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for 0HOY.L and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

0HOY.L(0HOY.L)

$43.56—Stale · unknown old

WatchlistAsk SA Chart

0HOY.L(0HOY.L)

LSE • Last print unknown ago

$43.56—Stale · unknown old

WatchlistAsk SA Chart Studio

0HOY.L(0HOY.L)

0HOY.L

9/27/26

Boston Scientific (0HOY.L)

Sunday

1:05 PM

ThesisBoston Scientific: the story is balanced — Electrophysiology segment growth rates, particularly FARAPULSE pulsed field ablation system adoption and market share…

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$20.1B	$21.3B	$22.2B
Rev. Growth	+19.9%	+5.9%	+4.4%
EPS	$1.96	$3.27	$3.40
EPS Growth	+55.6%	+67.0%	+3.9%
P/E (fwd)	22.2×	13.3×	12.8×

★ Analysts see FY2026 revenue reaching $21.3B — +5.9% growth in a single year.

What Moves the Stock

01Electrophysiology segment growth rates, particularly FARAPULSE pulsed field ablation system adoption and market share gains against Medtronic and Johnson & Johnson competitors
02FDA approval timelines and clinical trial readouts for pipeline products, especially structural heart devices (TAVR, LAA occluders) and neuromodulation platforms
03Hospital procedural volumes and elective surgery trends, which directly impact device utilization across cardiovascular and endoscopy categories
04Pricing dynamics in US and international markets, including Medicare reimbursement rate changes and hospital capital equipment budget cycles
05Acquisition integration execution and tuck-in M&A announcements that expand addressable markets or technology platforms
06Cardiovascular segment (~55-60% of revenue): Drug-eluting stents, structural heart devices, cardiac rhythm management systems including ICDs and pacemakers
07MedSurg segment (~30-35%): Endoscopy equipment, urology devices, neuromodulation systems for chronic pain management
08Peripheral Interventions (~10-15%): Vascular access products, thrombectomy systems, peripheral stents for arterial disease

FY2025 Snapshot

Revenue: $20.1B
Rev. Growth: +19.9%
Gross Margin: 65.0%
Op. Margin: 20.3%
Net Margin: 14.4%
Net Income: $2.9B
NI Growth: +55.7%
EPS: $1.96
1Y Return: -55.3%

0HOY.L Chart

My Notes

growth - Boston Scientific attracts growth-oriented investors seeking exposure to medical technology innovation and demographic tailwinds…
Rising interest rates moderately impact Boston Scientific through higher debt servicing costs on $5.8B in long-term debt…
Watch on earnings: US hospital admission and surgical procedure volumes as leading indicator of device utilization demand, Medicare physician fee schedule updates and CMS reimbursement rate changes for cardiovascular and endoscopy procedures, FDA 510(k) and PMA approval timelines for pipeline products, particularly FARAPULSE international expansion and structural heart devices.

One Sentence Summary:

Boston Scientific: the story is balanced — electrophysiology segment growth rates, particularly farapulse pulsed field ablation system adoption and market share gains against.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E (fwd)

22.2×

13.3×

12.8×

What Moves the Stock

01Electrophysiology segment growth rates, particularly FARAPULSE pulsed field ablation system adoption and market share gains against Medtronic and Johnson & Johnson competitors

02FDA approval timelines and clinical trial readouts for pipeline products, especially structural heart devices (TAVR, LAA occluders) and neuromodulation platforms

03Hospital procedural volumes and elective surgery trends, which directly impact device utilization across cardiovascular and endoscopy categories

04Pricing dynamics in US and international markets, including Medicare reimbursement rate changes and hospital capital equipment budget cycles

05Acquisition integration execution and tuck-in M&A announcements that expand addressable markets or technology platforms

06Cardiovascular segment (~55-60% of revenue): Drug-eluting stents, structural heart devices, cardiac rhythm management systems including ICDs and pacemakers

07MedSurg segment (~30-35%): Endoscopy equipment, urology devices, neuromodulation systems for chronic pain management

08Peripheral Interventions (~10-15%): Vascular access products, thrombectomy systems, peripheral stents for arterial disease

My Notes

growth - Boston Scientific attracts growth-oriented investors seeking exposure to medical technology innovation and demographic tailwinds…

Rising interest rates moderately impact Boston Scientific through higher debt servicing costs on $5.8B in long-term debt…

Watch on earnings: US hospital admission and surgical procedure volumes as leading indicator of device utilization demand, Medicare physician fee schedule updates and CMS reimbursement rate changes for cardiovascular and endoscopy procedures, FDA 510(k) and PMA approval timelines for pipeline products, particularly FARAPULSE international expansion and structural heart devices.